Opportunities
Search

Buyer: Ponta do Oeste - Sociedade de Promoção e Desenvolvimento da Zona Oeste da Madeira, SA | Notice type: cn-standard | Contract: services | Deadline: 2026-09-21

Buyer: VISTA college | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-21

Buyer: VILLE DE LORIENT | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-21

Buyer: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. - Einkauf B12 - Vergabestelle Bau | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-21

Buyer: European Commission, DG ENER - Energy | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-21

Buyer: Institution Eaux de la Montagne Noire | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-21

Buyer: Gemeente Hof van Twente | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-21

Buyer: Rijksinstituut voor Volksgezondheid en Milieu (RIVM) | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-21

Buyer: VARBERGS KOMMUN | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-21

Buyer: Västra Götalandsregionen | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-21

Buyer: Spaarnelanden N.V. | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-21

Buyer: SITREVA | Notice type: cn-standard | Contract: services | Deadline: 2026-09-21

Buyer: AreaCom - Agenzia regionale dell'Abruzzo per la Committenza | Notice type: cn-standard | Contract: services | Deadline: 2026-09-21

Buyer: CHU DE MONTPELLIER | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-21

Buyer: ProRail B.V. | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-21

Buyer: COMUNE DI CHIAVARI | Notice type: cn-standard | Contract: services | Deadline: 2026-09-21

The program in Foundations supports research in mathematical logic and the foundations of mathematics, including proof theory, recursion theory, model theory, set theory, and infinitary combinatorics. Conferences Principal Investigators should carefully read the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below) to obtain important information regarding the substance of proposals for conferences, workshops, summer/winter schools, and similar activities. Conference and workshop proposals should be submitted eight months before the requested start date.

The Combinatorics program supports research on discrete structures and includes algebraic, enumerative, existential, extremal, geometric, and probabilistic combinatorics, including graph theory. Conferences Principal Investigators should carefully read the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below) to obtain important information regarding the substance of proposals for conferences, workshops, summer/winter schools, and similar activities. Conference proposals must be submitted at least six months in advance of the conference, and in the same fiscal year (which begins October 1) if possible.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic areas. The platform product in development should address one of the FY26 PRMRP portfolio-specific strategic goals and address the health care needs of military Service Members, Veterans and their Families.Distinctive Features:Allows for multiple Principal Investigators (PIs). The proposed experiments may represent a single project led by a single PI, or it may consist of partnerships between principal investigators that will occur synergistically to advance a platform product. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).Requires a PI-convened external advisory board with patient advocate participation. The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $30M to fund approximately two Platform Clinical Transl...

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date.Supports three funding levels, each offered with and without a Planning Phase:Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants.Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants.Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants.Funding D...

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Scholar Award (NFRA-SA) supports early-career independent investigators (Scholars) joining the Neurofibromatosis Research Academy to pursue a neurofibromatosis project that may include basic, translational, and/or clinical research. The proposed research should address at least one of the FY26 NFRP Areas of Emphasis, under the leadership of the NFRA Director and Deputy Director. The overarching goal of the NFRA is to conduct innovative and impactful research in the field of neurofibromatosis disorders while developing successful, highly productive NF researchers in a collaborative research and career development environment.Distinctive Features:• Scholar: The Scholar, named as the Principal Investigator, must be less than 10 years of completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave).• Career Guide: This award mechanism requires each Scholar to designate a Career Guide for guidance. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, the application must identify a secondary Career Guide at the Scholar’s institution.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.Distinctive Features: This award mechanism offers two funding levels based on participation in two optional features:• Open Science Initiative: Catalyzes research for neurofibromatosis through early access to data and data sharing within the neurofibromatosis community.• Optional Qualified Collaborator: Encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists.The funding levels are defined as follows:• Level 1: Applications without an optional feature.• Level 2: Applications including one of the optional features.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Synergistic Idea Award (SIA) supports new ideas that represent synergistic approaches to neurofibromatosis (NF) research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.Distinctive Features:• Partnering Principal Investigators: One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. An additional one or two PI(s) will be identified as a Partnering PI. Each partner will be recognized as a PI, submit a separate application (even if the partners are at the same organization), and receive an individual award.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research. Studies supported by this award mechanism should lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.Distinctive Features:• Innovation: The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities.• Preliminary Data: Preliminary and/or published data is encouraged but not required.

Expected Impact:Proposals should present the concrete results which will be delivered by the activities and demonstrate how these results will contribute to the topic-specific impacts. This demonstration should rely on a solid analysis of the current situation, realistic assumptions and baselines, and establish clear causality links between proposed activities, results and impacts. In terms of qualitative impact, proposals under this topic should demonstrate how they will contribute to the following outcomes, as relevant:Improved Member States multilevel dialogues in the context of the achievement of the Union’s climate-neutrality objective and the different scenarios envisaged for energy and climate policies, including for the long term, and review progress.Improved coherence and synergies in strategies and measures across different stakeholders and governance levels.Improved engagement...